Processa Pharmaceuticals Stock Surges 150%, With A 6-Day Winning Spree
Processa Pharmaceuticals (PCSA) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 150% return. The company has gained about $11 Mil in value over the last 6 days, with its current market capitalization at about $7.5 Mil. The stock remains 45.8% below its value at the end of 2024. This compares with year-to-date returns of 14.8% for the S&P 500.
PCSA focuses on developing drug products addressing unmet medical needs, with lead candidate PCS499 in Phase 2B trials for treating ulcerative and non-ulcerative necrobiosis lipoidica.
If you seek an upside with less volatility than holding an individual stock, consider the High Quality Portfolio (HQ) – HQ has outperformed its benchmark – a combination of S&P 500, Russell, and S&P midcap index, and achieved returns exceeding 91% since its inception. Risk management is key – consider, what could long-term portfolio performance be if you blended 10% commodities, 10% gold, and 2% crypto with HQ’s performance metrics.
Comparing PCSA Stock Returns With The S&P 500
- The Smart Way to Own ANET: Collect 10% Before You Even Buy
- Triggers That Could Ignite the Next Rally In Meta Platforms Stock
- Can Coca-Cola Stock Withstand These Pressures?
- Fiserv Stock: Strong Cash Flow Poised for a Re-Rating?
- Comcast Stock Pullback: A Chance to Ride the Uptrend
- Has Accenture Stock Quietly Become a Value Opportunity?
The following table summarizes the return for PCSA stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | PCSA | S&P 500 |
|---|---|---|
| 1D | 33.0% | 0.6% |
| 6D (Current Streak) | 149.6% | 1.0% |
| 1M (21D) | 166.5% | 3.7% |
| 3M (63D) | 108.3% | 7.5% |
| YTD 2025 | -45.8% | 14.8% |
| 2024 | -86.8% | 23.3% |
| 2023 | -69.6% | 24.2% |
| 2022 | -77.6% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 51 S&P constituents with 3 days or more of consecutive gains and 78 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 21 | 45 |
| 4D | 15 | 19 |
| 5D | 9 | 7 |
| 6D | 2 | 2 |
| 7D or more | 4 | 5 |
| Total >=3 D | 51 | 78 |
Key Financials for Processa Pharmaceuticals (PCSA)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-11.5 Mil | $-12.1 Mil |
| Net Income | $-11.1 Mil | $-11.9 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-2.8 Mil | $-4.0 Mil |
| Net Income | $-2.8 Mil | $-3.9 Mil |
While PCSA stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.